Android app on Google Play

Questcor (QCOR) Names Michael Aldridge as SVP, Corp Development

January 28, 2013 6:35 AM EST Send to a Friend
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced the appointment of Michael Aldridge to the new position of Senior Vice President, Corporate Strategic Development. Mr. Aldridge's primary responsibilities will be the identification and development of partnership and acquisition opportunities to leverage Questcor's business model. Over time, such initiatives may include development programs or products complementary to Acthar (H.P. Acthar GelĀ®) and the evaluation of potential expansion into ex-US markets. Mr. Aldridge will report to Steve Cartt, Questcor's Chief Operating Officer.

Mr. Aldridge previously served as Chief Executive Officer, Managing Director, and member of the Board of Directors of Xenome Limited, where he led the strategic growth and direction of the privately held product development company.

Prior to that, Mr. Aldridge served as Chief Executive Officer, Managing Director and member of the Board of Directors of Peplin, Inc, which successfully developed a treatment for skin cancer. Peplin was sold to LEO Pharma in 2009. Before this, Mr. Aldridge held investment banking positions at leading international financial firms, including Wilson HTM Investment Group, Bear Stearns & Co., Volpe, Brown Whelan & Company, and SG Warburg Group.




You May Also Be Interested In


Related Categories

Management Changes

Related Entities

Bear Stearns

Add Your Comment